Skip to main content
Log in

Long-term neuro-functional disability in adult patients with community-acquired bacterial meningitis

  • Original Paper
  • Published:
Infection Aims and scope Submit manuscript

Abstract

Purpose

To investigate the prevalence of neuro-functional disability and its determinants 12 months after community-acquired bacterial meningitis (CABM) in adult patients.

Methods

In a prospective multicenter cohort study (COMBAT), all consecutive cases of CABM were enrolled and followed up for 12 months. Neuro-functional disability at 12 months was evaluated using a combination of the Glasgow Outcome Scale (functional disability), and the modified Rankin Disability Scale (physical disability). Factors associated with neuro-functional disability were identified by multivariate logistic regression.

Results

Among 281 patients, 84 (29.9%) patients exhibited neuro-functional disability at 12 months: 79 (28.1%) with functional disability and 51 (18.1%) with physical disability. Overall, 6 patients (2.1%) died during the follow-up. The most common pathogen identified was Streptococcus pneumoniae (131/272, 48.2%); 77/268 patients (28.7%) had a physical disability at hospital discharge. Factors independently associated with 12-month neuro-functional disability were a pneumococcal meningitis (adjusted OR = 2.8; 95% confidence interval (CI) = [1.3; 6.7]), the presence of a physical disability at hospital discharge (aOR = 2.3; 95%CI = [1.2; 4.4]) and the presence of behavioral disorders at hospital-discharge (aOR = 5.9; 95%CI = [1.6; 28.4]). Dexamethasone use was not significantly associated with neuro-functional disability (OR = 0.2; 95%CI = [< 0.1;1.3]).

Conclusion

Neuro-functional disability is frequently reported 12 months after CABM. Detailed neurological examination at discharge is needed to improve the follow-up.

Trial registration

NCT01730690.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

Availability of data and material

Data will be made upon reasonable request to the corresponding author.

Code availability

Not applicable.

References

  1. van de Beek D, Brouwer MC, Koedel U, Wall EC. Community-acquired bacterial meningitis. The Lancet. 2021;398:1171–83. https://doi.org/10.1016/S0140-6736(21)00883-7.

    Article  Google Scholar 

  2. Bijlsma MW, Brouwer MC, Kasanmoentalib ES, Kloek AT, Lucas MJ, Tanck MW, et al. Community-acquired bacterial meningitis in adults in the Netherlands, 2006–14: a prospective cohort study. Lancet Infect Dis. 2016;16:339–47. https://doi.org/10.1016/S1473-3099(15)00430-2.

    Article  PubMed  Google Scholar 

  3. Lucas MJ, Brouwer MC, van de Beek D. Neurological sequelae of bacterial meningitis. J Infect. 2016;73:18–27. https://doi.org/10.1016/j.jinf.2016.04.009.

    Article  PubMed  Google Scholar 

  4. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet. 1975;1:480–4. https://doi.org/10.1016/s0140-6736(75)92830-5.

    Article  CAS  PubMed  Google Scholar 

  5. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15:573–85. https://doi.org/10.1089/neu.1998.15.573.

    Article  CAS  PubMed  Google Scholar 

  6. Fayol P, Carrière H, Habonimana D, Preux P-M, Dumond J-J. French version of structured interviews for the Glasgow Outcome Scale: guidelines and first studies of validation. Ann Readapt Med Phys. 2004;47:142–56. https://doi.org/10.1016/j.annrmp.2004.01.004.

    Article  CAS  PubMed  Google Scholar 

  7. Rankin J. Cerebral vascular accidents in patients over the age of 60. II Prognosis Scott Med J. 1957;2:200–15. https://doi.org/10.1177/003693305700200504.

    Article  CAS  PubMed  Google Scholar 

  8. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed) 1988;296:316–20.

  9. des Portes V. Long-term follow-up of bacterial meningitis—sequels in children and adults: incidence, type, and assessment issues. Med Mal Infect. 2009;39:572–80. https://doi.org/10.1016/j.medmal.2009.02.019.

    Article  PubMed  Google Scholar 

  10. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351:1849–59. https://doi.org/10.1056/NEJMoa040845.

    Article  PubMed  Google Scholar 

  11. Kastenbauer S, Pfister H-W. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain. 2003;126:1015–25. https://doi.org/10.1093/brain/awg113.

    Article  PubMed  Google Scholar 

  12. Muralidharan R, Mateen FJ, Rabinstein AA. Outcome of fulminant bacterial meningitis in adult patients. Eur J Neurol. 2014;21:447–53. https://doi.org/10.1111/ene.12328.

    Article  CAS  PubMed  Google Scholar 

  13. Tubiana S, Varon E, Biron C, Ploy M-C, Mourvillier B, Taha M-K, et al. Community-acquired bacterial meningitis in adults: in-hospital prognosis, long-term disability and determinants of outcome in a multicentre prospective cohort. Clin Microbiol Infect. 2020;26:1192–200. https://doi.org/10.1016/j.cmi.2019.12.020.

    Article  CAS  PubMed  Google Scholar 

  14. Nguyen THM, Tran THC, Thwaites G, Ly VC, Dinh XS, Ho Dang TN, et al. Dexamethasone in Vietnamese adolescents and adults with bacterial meningitis. N Engl J Med. 2007;357:2431–40. https://doi.org/10.1056/NEJMoa070852.

    Article  CAS  PubMed  Google Scholar 

  15. van de Beek D, Cabellos C, Dzupova O, Esposito S, Klein M, Kloek AT, et al. ESCMID guideline: diagnosis and treatment of acute bacterial meningitis. Clin Microbiol Infect. 2016;22 Suppl 3:S37-62. https://doi.org/10.1016/j.cmi.2016.01.007.

    Article  PubMed  Google Scholar 

  16. Weir J, Steyerberg EW, Butcher I, Lu J, Lingsma HF, McHugh GS, et al. Does the extended Glasgow Outcome Scale add value to the conventional Glasgow Outcome Scale? J Neurotrauma. 2012;29:53–8. https://doi.org/10.1089/neu.2011.2137.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry. 1981;44:285–93. https://doi.org/10.1136/jnnp.44.4.285.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Combat study group; Principal investigator: X. Duval. Steering Committee: B. Hoen, B. Mourvillier, E. Varon, S. Tubiana, M. C. Ploy. Scientific committee: steering committee and the following members F. Caron, Pe. Bollaert, O. Gaillot, Mk. Taha, C. Poyart, S Bonacorsi, F. Vandenesch, E. Cambau, M Lecuit, A. Gravet, B. Frachet, T. Dde Broucker, D. Levy Bruhl, F. Raffi. Clinical centers: B. Abraham, F. Ader, E. Ancel, N. Anguel, L. Argaud, S. Arista, L. Armand-Lefevre, MN. Bachelier, S. Balavoine, R. Baraduc, G. Barnaud, G. Beraud, D. Bertei, E. Bessede, T. Billard Pomares, C. Biron, G. Blanchard-Marche, S. Bland, J. Boileau, C. Bornstain, S. Bourdon, A. Bousquet, S. Boyer, A. Bozorg-Grayeli, L. Bret, F. Bricaire, E. Brocas, M. Brun, J. Buret, C. Burucoa, E. Cambau, G. Camuset, C. Canevet, F. Caron, A. Carricajo, I. Casin, D. Cassignard, B. Castan, C. Cazanave, T. Challan-Belval, C. Chandesris, V. Chanteperdrix-Marillier, C. Chaplain, C. Charlier-Woerther, H. Chaussade, C. Chirouze, M. Chomarat, YE Claessens, B. Clair, D. Combaux, JM Conil, H. Cordel, P. Cormier, J. Cousson, P. Cronier, E. Cua, V. Daneluzzi, A. Dao Dubremetz, A. Defarcy, N. Degand, S. Dekeyser, D. Delaune, E. Denes, D. Descamps, Jl Desmaretz, E. Devaud, MC. Di Palma, S. Diamantis, JL. Diehl, J. Dimet, A. Dinh, X. Duval, E. Descloux, J. Colot, A. Emirian, O. Epaulard, L. Escaut, C. Fabe, T. Ferry, H. Fiette, C. Flateau, N. Fonsale, E. Forestier, N. Fortineau, T. Fraisse, F. Faibis, M. Froidure, S. Gabriel-Solean, A. Gagneux-Brunon, Garandeau, M. Garcia, V. Garnier, S. Gaudry, R. Ghozzi, A. Gravet, V. Gregoire-Faucher, M. Grosset, I. Gueit, D. Guelon, C. Guillet Caruba, T. Guimard, Y. Guimard, J. Guinard, T Hadou, JP. Helene, S. Henard, B. Henry, R. Hernu, AC. Hochart, B. Hoen, N. Idri, G. Illes, X. Jacob, S. Jaffuel, D. Jan, I. Jarrin, F. Jaureguy, C. Joseph, ME. Juvin, S. Kayal, F. Lacassin, M. Lafaurie, B. Lalanne, I. Lamaury, P. Lanotte, MF. Lartigue, Y. Latorre, P. Laudat, E. Laurens, H. Laurichesse, C. Le Brun, V. Le Moing, P. Le Turnier, H. Lecuyer, S. Ledru, L. Legout, C. Legrix, A. Lemaignen, C. Lemble, L. Lemee, S. Leotard, O. Lesens, P. Lesprit, M. Levast, F. Louis, L. Quaesaet, N. Luizy, S. Males, E. Malpote, G. Martin-Blondel, V. Martinez, R. Masson, O. Matray, A. Mbadi, F. Mechai, A. Merens, MC. Meyohas, G. Michel, A. Michon, J. Mootien Yoganaden, D. Morquin, S. Mouly, N. Mrozek, S. Nguyen, Y. Nguyen, A. Odinotte, M. Ogielska, E. Oziol, B. Page, E. Parisi-Duchene, T. Pasdeloup, S. Patrat-Delon, I. Patry, A. Pechinot, I. Pelloux, S. Picot, J. Pierre, L. Piroth, C. Plassart, P. Plessis, C. Ploton, MC. Ploy, L. Portel, M. Poupard, C. Poyart, T. Prazuck, F. Raffi, A. Ramanantsoa, C. Rapp, L. Raskine, J. Raymond, M. Revest, A. Riche, S. Robaday-Voisin, F. Robin, F. Roblot, JP. Romaszko, F. Rousseau, AL. Roux, C. Royer, M. Saada, D. Salmon, C. Saroufim, JL. Schmit, M. Sebire, C. Segonds, F. Sifaoui, V. Sivadon-Tardy, N. Soismier, K. Solen, A. Sommabere, O. Son, JP. Stahl, R. Steux, S. Sunder, F. Suy, D. Tande, J. Tankovic, S. Tigaud, B. Tourrand, N. Valin, N. Van Grunderbeeck, F. Vandenesch, E. Varon, R. Vatan, C. Venot, M. Vergnaud, Vernet, M. Vidal, V. Vitrat, D. Vittecoq, F. Vuotto, A. Chabrol, J. Cabalion. Coordination and statistical analyses (Clinical trial unit, Hôpitaux Universitaires Paris Nord Val de Seine, AP-HP, Paris): GORENNE Isabelle, LAOUENAN Cédric, MARCAULT Estelle, MENTRE France, PASQUET Blandine, ROY Carine, TUBIANA Sarah F. Mentré, C. Laouenan, I. Gorenne, E. Marcault, P. Manchon, B. Pasquet, C. Roy. Scientific partnership: SPLIF, CMIT, SRLF, SFM, REIVAC, SFORL, APNET. Partners: ORP (MC PLOY), GPIP/ACTIV (Corinne Levy). Fundings: French ministry of health, Inserm, SPILF, Pfizer pharmaceutical company. Sponsor: DRCI APHP. ClinicalTrial.gov identification number: NCT01730690.

X. Duval, B. Hoen, B. Mourvillier, E. Varon, S. Tubiana, M. C. Ploy, F. Caron, Pe. Bollaert, O. Gaillot, Mk. Taha, C. Poyart, S Bonacorsi, F. Vandenesch, E. Cambau, M. Lecuit, A. Gravet, B. Frachet, T. De Broucker, D. Levy Bruhl, F. Raffi, B. Abraham, F. Ader, E. Ancel, N. Anguel, L. Argaud, S. Arista, L. Armand-Lefevre, M. N. Bachelier, S. Balavoine, R. Baraduc, G. Barnaud, G. Beraud, D. Bertei, E. Bessede, T. Billard Pomares, C. Biron, G. Blanchard-Marche, S. Bland, J. Boileau, C. Bornstain, S. Bourdon, A. Bousquet, S. Boyer, A. Bozorg-Grayeli, L. Bret, F. Bricaire, E. Brocas, M. Brun, J. Buret, C. Burucoa, E. Cambau, G. Camuset, C. Canevet, F. Caron, A. Carricajo, I. Casin, D. Cassignard, B. Castan, C. Cazanave, T. Challan-Belval, C. Chandesris, V. Chanteperdrix-Marillier, C. Chaplain, C. Charlier-Woerther, H. Chaussade, C. Chirouze, M. Chomarat, Y. E. Claessens, B. Clair, D. Combaux, J. M. Conil, H. Cordel, P. Cormier, J. Cousson, P. Cronier, E. Cua, V. Daneluzzi, A. Dao Dubremetz, A. Defarcy, N. Degand, S. Dekeyser, D. Delaune, E. Denes, D. Descamps, Jl. Desmaretz, E. Devaud, M. C. Di Palma, S. Diamantis, J. L. Diehl, J. Dimet, A. Dinh, X. Duval, E. Descloux, J. Colot, A. Emirian, O. Epaulard, L. Escaut, C. Fabe, T. Ferry, H. Fiette, C. Flateau, N. Fonsale, E. Forestier, N. Fortineau, T. Fraisse, F. Faibis, M. Froidure, S. Gabriel-Solean, A. Gagneux-Brunon, Garandeau, M. Garcia, V. Garnier, S. Gaudry, R. Ghozzi, A. Gravet, V. Gregoire-Faucher, M. Grosset, I. Gueit, D. Guelon, C. Guillet Caruba, T. Guimard, Y. Guimard, J. Guinard, T Hadou, J. P. Helene, S. Henard, B. Henry, R. Hernu, A. C. Hochart, B. Hoen, N. Idri, G. Illes, X. Jacob, S. Jaffuel, D. Jan, I. Jarrin, F. Jaureguy, C. Joseph, M. E. Juvin, S. Kayal, F. Lacassin, M. Lafaurie, B. Lalanne, I. Lamaury, P. Lanotte, M. F. Lartigue, Y. Latorre, P. Laudat, E. Laurens, H. Laurichesse, C. Le Brun, V. Le Moing, P. Le Turnier, H. Lecuyer, S. Ledru, L. Legout, C. Legrix, A. Lemaignen, C. Lemble, L. Lemee, S. Leotard, O. Lesens, P. Lesprit, M. Levast, F. Louis, L. Quaesaet, N. Luizy, S. Males, E. Malpote, G. Martin-Blondel, V. Martinez, R. Masson, O. Matray, A. Mbadi, F. Mechai, A. Merens, M. C. Meyohas, G. Michel, A. Michon, J. Mootien Yoganaden, D. Morquin, S. Mouly, N. Mrozek, S. Nguyen, Y. Nguyen, A. Odinotte, M. Ogielska, E. Oziol, B. Page, E. Parisi-Duchene, T. Pasdeloup, S. Patrat-Delon, I. Patry, A. Pechinot, I. Pelloux, S. Picot, J. Pierre, L. Piroth, C. Plassart, P. Plessis, C. Ploton, M. C. Ploy, L. Portel, M. Poupard, C. Poyart, T. Prazuck, F. Raffi, A. Ramanantsoa, C. Rapp, L. Raskine, J. Raymond, M. Revest, A. Riche, S. Robaday-Voisin, F. Robin, F. Roblot, J. P. Romaszko, F. Rousseau, A. L. Roux, C. Royer, M. Saada, D. Salmon, C. Saroufim, J. L. Schmit, M. Sebire, C. Segonds, F. Sifaoui, V. Sivadon-Tardy, N. Soismier, K. Solen, A. Sommabere, O. Son, JP. Stahl, R. Steux, S. Sunder, F. Suy, D. Tande, J. Tankovic, S. Tigaud, B. Tourrand, N. Valin, N. Van Grunderbeeck, F. Vandenesch, E. Varon, R. Vatan, C. Venot, M. Vergnaud, Vernet, M. Vidal, V. Vitrat, D. Vittecoq, F. Vuotto, A. Chabrol, J. Cabalion, S. Tubiana, F. Mentré, C. Laouénan, I. Gorenne, E. Marcault, P. Manchon, B. Pasquet, C. Roy

Funding

The cohort was funded by the French ministry of health, APHP DRCI, Inserm, French society of infectious diseases, and Pfizer pharmaceutical company.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to Xavier Duval.

Ethics declarations

Conflict of interest

We have read and understood the Infection policy on declaration of interests and have no relevant interests to declare.

Ethics approval

The study was approved by the institutional Ethics Committee Ile-de-France 4 (IRB #00003835, approval #2012-16NI) and by the French Data Protection Authority (approval ECY/FLR/AR128794).

Consent to participate

All participants provided consent to participate before entering the study.

Consent for publication

Not applicable.

Additional information

The members of the COMBAT study group are mentioned in Acknowledgements section.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 30 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Akroum, S., Tubiana, S., de Broucker, T. et al. Long-term neuro-functional disability in adult patients with community-acquired bacterial meningitis. Infection 50, 1363–1372 (2022). https://doi.org/10.1007/s15010-022-01855-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-022-01855-2

Keywords

Navigation